

**DSP-Visulex Treatment of a Pan Uveitis Model Published in the *Journal of Ocular Pharmacology and Therapeutics***

Salt Lake City, UT – November 8, 2017 – Aciont Inc. announced today that results from preclinical studies of its DSP-Visulex technology have been published in the November issue of the Journal of Ocular Pharmacology and Therapeutics, volume 33, number 9, under the title ***“Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in the Treatment of Experimental Uveitis Rabbit.”***

Dr. Kongnara Papangkorn, VP of Product Development at Aciont, said “We are pleased to share key data of DSP-Visulex to the science community. In this study, we took a chronic uveitis model that has been used in drug screening for posterior uveitis including dexamethasone implants. We found that some treatment regimens of DSP-Visulex can effectively suppress ocular inflammation in this chronic uveitis model.”

Papangkorn further added, “Treatment of inflammation in the posterior eye tissues topically from the front of the eye without invasively intruding the eye globe is a novel modality. We also found that DSP Visulex had excellent safety and tolerability while treating such challenging uveitis rabbit model.”

The abstract and full article can be found in the journal and on the publisher’s website.

<http://online.liebertpub.com/doi/pdf/10.1089/jop.2017.0053>

DSP-Visulex is a noninvasive drug delivery system of dexamethasone sodium phosphate (DSP). It utilizes a combination of a proprietary high concentration DSP solution and Visulex-P drug applicator technology to enable a simple administration of DSP to treat inflammation conditions of both anterior and posterior eye tissues. The DSP-Visulex study was supported by the NEI SBIR Grant R44EY014772.